This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Articles

Treatment of Major Depression: Is Improvement Enough?

Ian Nicol Ferrier, BSc (Hon), FRCP, FRCPsych, MD (Hon)

Published: June 1, 1999

Article Abstract

The goals of antidepressant treatment are to induce remission and prevent relapse or recurrence. While response is the standard criterion applied to comparisons of antidepressant drugs indicating an improvement from baseline, the more stringent criterion of remission is more relevant to clinical practice because it indicates that the patient is asymptomatic (i.e., “well”). Patients may enter into a remission or partial remission, which is characterized by the presence of residual symptoms and an increased risk of relapse, impairment, and suicide. Studies with many antidepressants demonstrate response rates of 50% to 60% but remission rates of only 20% to 30%. Venlafaxine is an antidepressant that is characterized as a serotonin-norepinephrine reuptake inhibitor (SNRI). Using the criterion of remission, placebo-controlled and comparative trials demonstrate a higher remission rate with venlafaxine than with other antidepressants, thus improving the proportion of patients who are “well.” Selection of optimal antidepressant therapy should consider drugs that have the greatest potential to induce remission.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 60

Quick Links: Depression (MDD)

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Original Research

Prevalence and Correlates of Obsessive-Compulsive Symptoms in Individuals With Schizophrenia, Schizoaffective Disorder, or Bipolar Disorder

Prevalence and correlates of obsessive-compulsive symptoms and OCD were identified from the case records of over 22,500...

Read More...